UBS analyst AJ Rice lowered the firm’s price target on Acadia Healthcare (ACHC) to $24 from $28 and keeps a Buy rating on the shares. Acadia lowered its 2025 guidance due to a $50M liability reserve accrual expected in Q4, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACHC:
- Leerink downgrades Acadia Healthcare on ‘real risk’ of legal liabilities
- Acadia Healthcare price target lowered to $25 from $30 at KeyBanc
- BofA downgrades Acadia Healthcare to Underperform after another guidance cut
- Acadia Healthcare downgraded to Underperform from Neutral at BofA
- Acadia Healthcare downgraded to Market Perform from Outperform at Leerink